VEGF: a surrogate marker for peripheral vascular disease.
This study aims to evaluate the value of VEGF as a surrogate marker for peripheral vascular disease (PVD). Prior to treatment, serum VEGF levels were evaluated by enzyme-linked immunosorbent assay (ELISA) in 293 PVD patients. Risk factors and clinical parameters of PVD were documented. Twenty-six age-matched healthy volunteers served as controls. Serum VEGF values strongly correlated with Fontaine stages (p<0.006, stage IV vs. controls). High VEGF values prior to treatment were associated with poor outcome. Serum VEGF appears to indicate the severity of PVD and might serve as a surrogate indicator of disease severity.
Stehr
A
A
Vascular and Endovascular Surgery, University of Regensburg, Franz-Josef-Strauss-Allee 11, 93042 Regensburg, Germany.
Töpel
I
I
Müller
S
S
Unverdorben
K
K
Geissler
E K
EK
Kasprzak
P M
PM
Schlitt
H J
HJ
Steinbauer
M
M
D000368:Aged; D015415:Biomarkers / Q000097:blood; D016022:Case-Control Studies; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D008297:Male; D016491:Peripheral Vascular Diseases / Q000097:blood*; D011237:Predictive Value of Tests; D011446:Prospective Studies; D012720:Severity of Illness Index; D015854:Up-Regulation; D042461:Vascular Endothelial Growth Factor A / Q000097:blood*
D015415:Biomarkers; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A